Evidence map›Paper›PMID 24610909›Full record

ArticleJournal of the National Cancer Institute2014

Prostate cancer mortality in areas with high and low prostate cancer incidence.

Pär Stattin, Sigrid Carlsson, Benny Holmström, Andrew Vickers, Jonas Hugosson, Hans Lilja, Håkan Jonsson

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Pär StattinAffiliations of authors: Department of Surgery and Perioperative Sciences, Urology and Andrology (PS, BH) and Department of Radiation Sciences, Oncology (HJ), Umeå University, Umeå, Sweden; Department of Surgery, Urology Service (PS, SC), Department of Epidemiology and Biostatistics (AV), Department of Laboratory Medicine (HL), Department of Surgery (HL), and Department of Medicine (HL), Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Urology, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden (SC, JH); Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK (HL); Institute of Biomedical Technology, University of Tampere, Tampere, Finland (HL); Department of Laboratory Medicine in Malmö, Lund University, Malmö, Sweden (HL).
Sigrid Carlsson
Benny Holmström
Andrew Vickers
Jonas Hugosson
Hans Lilja
Håkan Jonsson

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Long-term prediction of prostate cancer death from kallikreins measured in bloodR33CA127768 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LILJA, HANS GÖSTA · 2010 to 2011
$692k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R33 CA127768
6 · The paper itself

Abstract

backgroundThe effect of prostate-specific antigen (PSA) screening on prostate cancer mortality remains debated, despite evidence from randomized trials. We investigated the association between prostate cancer incidence, reflecting uptake of PSA testing, and prostate cancer mortality.

methodsThe study population consisted of all men aged 50 to 74 years residing in eight counties in Sweden with an early increase in prostate cancer incidence and six counties with a late increase during two time periods. Incidence of metastatic prostate cancer was investigated in the period from 2000 to 2009, and prostate cancer-specific mortality and excess mortality were investigated in the period from 1990 to 1999 and the period from 2000 to 2009 by calculating rate ratios for high- vs low-incidence counties and rate ratios for the period from 2000 to 2009 vs the period from 1990 to 1999 within these two groups. All statistical tests were two-sided.

resultsThere were 4528134 person-years at risk, 1577 deaths from prostate cancer, and 1210 excess deaths in men with prostate cancer in high-incidence counties and 2471373 person-years at risk, 985 prostate cancer deaths, and 878 excess deaths in low-incidence counties in the period from 2000 to 2009. Rate ratios in counties with high vs low incidence adjusted for time period were 0.81 (95% confidence interval [CI] = 0.73 to 0.90) for prostate cancer- specific mortality and 0.74 (95% CI = 0.64 to 0.86) for excess mortality, and the rate ratio of metastatic prostate cancer was 0.85 (95% CI = 0.79 to 0.92).

conclusionsThe lower prostate cancer mortality in high-incidence counties reflecting a high PSA uptake suggests that more-intense as compared with less-intense opportunistic PSA screening reduces prostate cancer mortality.

Indexed as

Early Detection of CancerMass ScreeningAgedBiomarkers, TumorHumansIncidenceMaleMiddle AgedMortalityProstate-Specific AntigenProstatic NeoplasmsRegistriesSwedenBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID24610909
PMCPMC3982781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.